2023 World Conference on Lung Cancer (Posters)-EP12.01. Successful Aumolertinib Treatment of Activated EGFR Mutation NSCLC Patients with Interstitial Pneumonia Induced by Osimertinib

EP12.01. Successful Aumolertinib Treatment of Activated EGFR Mutation NSCLC Patients with Interstitial Pneumonia Induced by Osimertinib - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated the safety and efficacy of aumolertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with metastatic non-small cell lung cancer (NSCLC) who developed interstitial lung disease (ILD) after treatment with osimertinib. The aim was to provide a new treatment option for these patients and assess its impact on survival. <br /><br />The study included 16 patients with stage IIIA-IV EGFR-mutated lung adenocarcinoma who developed ILD after receiving osimertinib. Following the development of ILD, osimertinib was discontinued and patients received methylprednisolone and other symptomatic treatments. Once the patients' symptoms improved, they were rechallenged with aumolertinib. <br /><br />Results showed that aumolertinib treatment was successful in all patients, with a 100% conversion success rate within 3 months and a disease control rate of 100%. Four patients achieved partial response, and eight patients were still receiving treatment. The median duration of treatment was 15 months, and no grade 3 or above adverse reactions occurred. Importantly, there were no cases of ILD recurrence during aumolertinib treatment. <br /><br />These findings suggest that aumolertinib could be a viable treatment option for patients who develop ILD after treatment with osimertinib. It was associated with improved survival and did not cause ILD. ILD is a potentially fatal adverse event, and the study's results provide hope for patients facing this complication.

Asset Subtitle

Enguo Chen

Meta Tag

Speaker Enguo Chen

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

aumolertinib

EGFR

tyrosine kinase inhibitor

metastatic non-small cell lung cancer

interstitial lung disease

osimertinib

treatment option

survival

lung adenocarcinoma

ILD